RESUMEN
OBJECTIVE: Women with history of breast cancer (HBC) frequently suffer from vulvovaginal atrophy (VVA). European Vulvovaginal Epidemiology Survey (EVES) sub-analysis assesses the impact of HBC on VVA, sexual life and quality of life (QoL) in postmenopausal women. MATERIALS AND METHODS: Women with at least one VVA symptom aged 45-75 years were included. EuroQol (EQ-5D-3L) and Day-to-Day Impact of Vaginal Aging (DIVA) questionnaires were filled to investigate QoL. VVA diagnosis was confirmed with objective gynecological examination. Comparison of postmenopausal women with and without HBC, and evaluation of treatment impact on VVA were performed. RESULTS: 1985 postmenopausal women without HBC and 175 with HBC were included. VVA was confirmed in 90.4% of women without HBC and 91.4% of women with HBC. There were no differences in VVA symptoms severity or vulvovaginal discomfort between groups. However, women with HBC who had completed treatment and had surgery 11-20 years previously versus those without HBC presented significantly worse Vaginal Health Index scores, as well as a higher prevalence of VVA objective diagnosis, although their overall symptom severity score was lower. Health status and QoL comparisons were similar. CONCLUSIONS: Results support a similar burden in terms of VVA prevalence and symptoms, QoL and sexual function in postmenopausal women with and without HBC.
Asunto(s)
Vaginitis Atrófica/epidemiología , Neoplasias de la Mama/epidemiología , Anciano , Antineoplásicos/efectos adversos , Vaginitis Atrófica/inducido químicamente , Vaginitis Atrófica/psicología , Neoplasias de la Mama/tratamiento farmacológico , Femenino , Humanos , Italia/epidemiología , Persona de Mediana Edad , Posmenopausia , Prevalencia , Calidad de Vida , Conducta Sexual , España/epidemiología , Encuestas y CuestionariosRESUMEN
OBJECTIVE: To reappraise the definition of Genitourinary syndrome of menopause (GSM) and to evaluate the prevalence and effect of GSM on quality of life in Turkish postmenopausal women. METHODS: A multicenter, cross-sectional, and observational study was designed. Four hundred three postmenopausal women between the ages of 43-75 who attended Urology and Gynecology clinics between November 2019 and April 2020 were included.They were divided into 2 groups: Group I (GSM, n:288, 71.5%) and Group II (non-GSM, n:115, 28.5%). Demographic data, presence and intensity of genitourinary symptoms were recorded. The impact of menopause and urinary incontinence on quality of life was evaluated with the Menopause-Specific Quality of Life Questionnaire and the King's Health Questionnaire. RESULTS: The most common symptoms were vaginal dryness (66.2%), reduced lubrication (55.3%), and urgency (54.8%). Urinary incontinence was present in 39.2% of women. Worse quality of life in terms of psychosocial and sexual domains of the Menopause-Specific Quality of Life Questionnaire was significant in Group 1 (P < .001). Group 1 had significantly worse scores for all domains of the King's Health Questionnaire. Only the rate of patients with stress incontinence was higher in Group 1. However, the percentage of moderate and severe symptoms for all types of incontinence was higher in Group 1. Although the prevalence of GSM was 71.5% according to our definition, the percentage of patients previously visiting healthcare professionals for their symptoms was low (52.8%). CONCLUSION: Our findings show that urologists and gynecologists should question both symptom groups of postmenopausal women, even if patients do not bring up genitourinary symptoms.
Asunto(s)
Vaginitis Atrófica/epidemiología , Posmenopausia/fisiología , Calidad de Vida , Disfunciones Sexuales Fisiológicas/epidemiología , Incontinencia Urinaria/epidemiología , Adulto , Anciano , Vaginitis Atrófica/fisiopatología , Vaginitis Atrófica/psicología , Estudios Transversales , Femenino , Humanos , Persona de Mediana Edad , Posmenopausia/psicología , Disfunciones Sexuales Fisiológicas/fisiopatología , Disfunciones Sexuales Fisiológicas/psicología , Síndrome , Turquía/epidemiología , Incontinencia Urinaria/fisiopatología , Incontinencia Urinaria/psicologíaRESUMEN
In her lifetime, a woman is highly likely to develop at least one lower urinary tract infection. Early detection and treatment are key. Being aware of predisposing factors for infection and understanding appropriate diagnosis and treatment regimens will help nurses in both primary and acute care manage these patients correctly. This will not only benefit patients but will also help prevent incorrect antimicrobial management and avoid unplanned admissions. This aim of this article is to provide nurses with the information they need to best advise both colleagues and patients on how to manage lower urinary tract infections in women.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Asintomáticas , Farmacorresistencia Bacteriana , Infecciones Urinarias/tratamiento farmacológico , Factores de Edad , Antiinfecciosos Urinarios/uso terapéutico , Vaginitis Atrófica/tratamiento farmacológico , Vaginitis Atrófica/epidemiología , Bacteriuria/diagnóstico , Bacteriuria/tratamiento farmacológico , Bacteriuria/prevención & control , Bacteriuria/orina , Anticoncepción , Técnicas de Cultivo , Terapia de Reemplazo de Estrógeno , Femenino , Hipuratos/uso terapéutico , Humanos , Metenamina/análogos & derivados , Metenamina/uso terapéutico , Nitritos/orina , Educación del Paciente como Asunto , Probióticos/uso terapéutico , Recurrencia , Factores de Riesgo , Conducta Sexual , Infecciones Urinarias/diagnóstico , Infecciones Urinarias/prevención & controlRESUMEN
This study investigated the prevalence and risk factors of urinary incontinence (UI) among perimenopausal women in Wuhan. A cross-sectional survey was performed on 1067 women aged 40-65 years sampled in Wuhan urban area from April to October 2014. Information about demographic characteristics, menstruation, parity and UI symptoms was collected using a questionnaire. The data were evaluated by Chi-square test and multiple Logistic regression analysis. The prevalence rate of UI was 37.2%, with stress UI (32.2%) being more prevalent than urgency UI (21.6%) and mixed UI (16.6%). 31.2% women with UI stated that UI had negative impact on their life. Risk factors for UI included menstrual disorder, menopause, overweight, perineal laceration, atrophic vaginitis, constipation and pelvic organ prolapse. Appropriate investigation apropos the factors associated with UI should be performed to diminish its impact on women's life.
Asunto(s)
Perimenopausia/fisiología , Incontinencia Urinaria/epidemiología , Adulto , Anciano , Vaginitis Atrófica/epidemiología , Vaginitis Atrófica/fisiopatología , Estreñimiento/epidemiología , Estreñimiento/fisiopatología , Femenino , Humanos , Laceraciones/epidemiología , Laceraciones/fisiopatología , Ciclo Menstrual/fisiología , Persona de Mediana Edad , Sobrepeso/epidemiología , Sobrepeso/fisiopatología , Prolapso de Órgano Pélvico/epidemiología , Prolapso de Órgano Pélvico/fisiopatología , Embarazo , Factores de Riesgo , Encuestas y Cuestionarios , Incontinencia Urinaria/fisiopatologíaRESUMEN
La atrofia vaginal, causada por el déficit estrogénico, es responsable de la aparición de síntomas que afectan la calidad de vida. El tratamiento tendrá como objetivo restaurar la fisiología urogenital y aliviar los síntomas. Para síntomas como la sequedad vaginal o la dispareunia asociada con atrofia vaginal, la primera línea de tratamiento son los hidratantes (evidencia IA) y lubricantes vaginales (evidencia IIB). Si no proporcionan una adecuada mejora de los síntomas o ante síntomas moderados-intensos, se utilizarán estrógenos. Los estrógenos son los tratamientos más efectivos. En casos de solo atrofia vaginal, la elección será la terapia con estrógenos locales (TEL) (evidencia IA). En casos que coexistan con sintomatología vasomotora que afecte a la calidad de vida, la elección será la terapia hormonal sistémica (evidencia IA). Las dosis bajas de estrógenos son el tratamiento farmacológico hormonal de primera línea para la vaginitis atrófica (AU)
Vaginal atrophy, caused by estrogen deficiency, leads to the development of symptoms that affect quality of life. Treatment aims to restore the urogenital physiology and relieve symptoms. For symptoms such as vaginal dryness or dyspareunia associated with vaginal atrophy, the first line treatments are moisturizers (Evidence IA) and vaginal lubricants (Evidence IIB). If these treatments fail to provide sufficient improvement in symptoms or when the symptoms are moderate-to-intense, estrogen can be used. Estrogens are the most effective treatments. In patients with vaginal atrophy alone, the choice is local estrogen therapy (Evidence IA). In patients who also have vasomotor symptoms affecting quality of life, treatment consists of systemic hormone replacement therapy (Evidence IA). Low dose oestrogens are a first line pharmacological treatment for atrophic vaginitis (AU)